The AKT-mTOR Signaling Pathway for Drug Response Prediction and Prognostic Signatures

[1]  E. Coppin,et al.  Flow cytometric analysis of intracellular phosphoproteins in human monocytes , 2017, Cytometry. Part B, Clinical cytometry.

[2]  E. Petricoin,et al.  Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors , 2015, Oncotarget.

[3]  M. Masuda,et al.  Signaling pathway profiling by reverse-phase protein array for personalized cancer medicine. , 2015, Biochimica et biophysica acta.

[4]  T. Mukohara,et al.  PI3K mutations in breast cancer: prognostic and therapeutic implications , 2015, Breast cancer.

[5]  K. Darwiche,et al.  HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas. , 2015, Lung cancer.

[6]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[7]  Jin-Ling Tang,et al.  The prognostic value of phosphorylated Akt in breast cancer: a systematic review , 2015, Scientific Reports.

[8]  Jean J. Zhao,et al.  PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting , 2014, Nature Reviews Cancer.

[9]  M. Ando,et al.  Activated PI3K/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Zhi-qin Fu,et al.  Prognostic value of phospho‐Akt in patients with non‐small cell lung carcinoma: A meta‐analysis , 2014, International journal of cancer.

[11]  E. Petricoin,et al.  A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer , 2014, Breast Cancer Research and Treatment.

[12]  K. Zhao,et al.  Activation of PI3K/Akt/mTOR pathway and dual inhibitors of PI3K and mTOR in endometrial cancer. , 2014, Current medicinal chemistry.

[13]  C. Cui,et al.  Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma , 2014, BMC Cancer.

[14]  E. Petricoin,et al.  Pilot phase I/II personalized therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab. , 2014, Journal of proteome research.

[15]  Jiri Polivka,et al.  Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. , 2014, Pharmacology & therapeutics.

[16]  Jing Cai,et al.  The role of the PTEN/PI3K/Akt pathway on prognosis in epithelial ovarian cancer: a meta-analysis. , 2014, The oncologist.

[17]  A. Pandiella,et al.  Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis , 2014, PloS one.

[18]  R. O'Regan,et al.  The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers , 2014, Therapeutic advances in medical oncology.

[19]  G. Lazaridis,et al.  Prognostic and predictive value of p-Akt, EGFR, and p-mTOR in early breast cancer , 2014, Strahlentherapie und Onkologie.

[20]  H. Höfler,et al.  Activation of the PI3K/AKT pathway correlates with prognosis in stage II colon cancer , 2014, British Journal of Cancer.

[21]  Emanuel F Petricoin,et al.  Preparation and Use of Reverse Protein Microarrays , 2014, Current protocols in protein science.

[22]  C. Rommel,et al.  PI3K and cancer: lessons, challenges and opportunities , 2014, Nature Reviews Drug Discovery.

[23]  Z. Qiu,et al.  The Prognostic Value of Phosphorylated AKT Expression in Non-Small Cell Lung Cancer: A Meta-Analysis , 2013, PloS one.

[24]  T. Petit,et al.  Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study , 2013, Targeted Oncology.

[25]  S. Vacher,et al.  PIK3R1 underexpression is an independent prognostic marker in breast cancer , 2013, BMC Cancer.

[26]  D. Sgroi,et al.  The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials , 2013, Breast Cancer Research.

[27]  Benjamin J. Raphael,et al.  Mutational landscape and significance across 12 major cancer types , 2013, Nature.

[28]  Jun Li,et al.  TCPA: a resource for cancer functional proteomics data , 2013, Nature Methods.

[29]  E. Petricoin,et al.  Protein pathway activation mapping of colorectal metastatic progression reveals metastasis-specific network alterations , 2013, Clinical & Experimental Metastasis.

[30]  P. V. van Diest,et al.  Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment , 2012, Breast Cancer Research.

[31]  L. Skoog,et al.  Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit , 2012, Breast Cancer Research and Treatment.

[32]  E. Petricoin,et al.  Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping , 2012, Clinical Cancer Research.

[33]  Ronald J. Moore,et al.  Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum , 2012, Proceedings of the National Academy of Sciences.

[34]  Brett Houser,et al.  Bio-Rad’s Bio-Plex® suspension array system, xMAP technology overview , 2012, Archives of physiology and biochemistry.

[35]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[36]  H. Kluger,et al.  Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer , 2011, Journal of Translational Medicine.

[37]  J. Blenis,et al.  The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. , 2011, Trends in biochemical sciences.

[38]  Hyun-Ah Kim,et al.  Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer , 2011, Breast Cancer Research and Treatment.

[39]  Walter Kolch,et al.  Functional proteomics to dissect tyrosine kinase signalling pathways in cancer , 2010, Nature Reviews Cancer.

[40]  Lei Jin,et al.  Development and application of ‘phosphoflow’ as a tool for immunomonitoring , 2010, Expert review of vaccines.

[41]  M. Duffy,et al.  Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib , 2010, Molecular Cancer Therapeutics.

[42]  J. Engelman,et al.  The PI3K pathway as drug target in human cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Qin Fu,et al.  Comparison of multiplex immunoassay platforms. , 2010, Clinical chemistry.

[44]  K. Cederbrant,et al.  Meso Scale Discovery and Luminex Comparative Analysis of Calbindin D28K , 2009, Journal of biomedicine & biotechnology.

[45]  P. Auclair,et al.  Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study , 2009, BMC Cancer.

[46]  J. Nunès,et al.  Analysis of Signaling Events by Dynamic Phosphoflow Cytometry , 2009, Science Signaling.

[47]  Jeffrey A. Engelman,et al.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.

[48]  Pixu Liu,et al.  Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.

[49]  Xu Shi,et al.  Quantification of Cardiovascular Biomarkers in Patient Plasma by Targeted Mass Spectrometry and Stable Isotope Dilution* , 2009, Molecular & Cellular Proteomics.

[50]  R. Aebersold,et al.  Selected reaction monitoring for quantitative proteomics: a tutorial , 2008, Molecular systems biology.

[51]  Pier Paolo Pandolfi,et al.  The PTEN–PI3K pathway: of feedbacks and cross-talks , 2008, Oncogene.

[52]  M. Mann,et al.  Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. , 2008, Molecular cell.

[53]  Zhi Hu,et al.  An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. , 2008, Cancer research.

[54]  Bert Vogelstein,et al.  The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations , 2007, Science.

[55]  L. Liotta,et al.  Reverse-phase protein microarrays: application to biomarker discovery and translational medicine , 2007, Expert review of molecular diagnostics.

[56]  P. Workman,et al.  Application of meso scale technology for the measurement of phosphoproteins in human tumor xenografts. , 2007, Assay and drug development technologies.

[57]  Yuval Inbar,et al.  Mechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic Subunit , 2007, Science.

[58]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[59]  Garry P Nolan,et al.  Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling , 2006, Nature Methods.

[60]  W. de Jager,et al.  Solid-phase and bead-based cytokine immunoassay: a comparison. , 2006, Methods.

[61]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.

[62]  M. Loda,et al.  The oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cells , 2005 .

[63]  J. Engelman,et al.  Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. , 2005, Cancer research.

[64]  J. Bartlett,et al.  AKT activation predicts outcome in breast cancer patients treated with tamoxifen , 2005, The Journal of pathology.

[65]  M. Berger,et al.  Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. , 2005, Journal of the National Cancer Institute.

[66]  J. Coon,et al.  EGFR mutations and pAKT expression as potential predictors of gefitinib efficacy in non-small cell lung cancer (NSCLC) patients (pts) , 2005 .

[67]  Elisa Rossi,et al.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.

[68]  K. O'Byrne,et al.  Phospho-Akt Expression Is Associated with a Favorable Outcome in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[69]  S. Hirohashi,et al.  Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma , 2005, Cancer.

[70]  F. Cappuzzo,et al.  Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. , 2004, Journal of the National Cancer Institute.

[71]  M. Paul,et al.  Tyrosine kinase – Role and significance in Cancer , 2004, International journal of medical sciences.

[72]  H. Lee,et al.  Akt/PKB activation in gastric carcinomas correlates with clinicopathologic variables and prognosis , 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[73]  M. White,et al.  c-Jun N-terminal Kinase (JNK) Mediates Feedback Inhibition of the Insulin Signaling Cascade* , 2003, The Journal of Biological Chemistry.

[74]  D. Rimm,et al.  Automated subcellular localization and quantification of protein expression in tissue microarrays , 2002, Nature Medicine.

[75]  P. Dennis,et al.  Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. , 2002, Molecular cancer therapeutics.

[76]  E. Petricoin,et al.  Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front , 2001, Oncogene.

[77]  Michael J. Fry,et al.  Phosphatidylinositol-3-OH kinase direct target of Ras , 1994, Nature.

[78]  James V. Watson,et al.  Introduction to Flow Cytometry , 1991 .

[79]  L. Huber,et al.  Mapping in vivo signal transduction defects by phosphoproteomics. , 2012, Trends in molecular medicine.